Neutron Holdings received a buy rating due to its strong 29% year-over-year revenue growth to $887 million in 2025 and a 32% revenue increase in Q1 2026. The company also reported healthy unit economics with a 24.6% adjusted EBITDA margin and $103.8 million in free cash flow, supported by a one-year payback period on fleet investments. Despite risks from capital expenditure intensity, Uber dependence, and regulatory factors, its valuation multiples of 7.3x EV/EBITDA and 16.9x EV/FCF for 2026 make it an attractive investment opportunity amid urbanization trends.
The U.S. Bankruptcy Court for the Central District of California confirmed the Plan of Liquidation for Oceanwide Plaza LLC, enabling the $470 million sale of the stalled Downtown Los Angeles development to KPC Square, a joint venture between KPC Grou...
Axsome Therapeutics received an "Outperform" rating from BMO Capital due to significant progress in its drug pipeline, including FDA acceptance of its NDA for AXS-12, a narcolepsy treatment with a PDUFA date set for May 1, 2027. The company is also a...
Novartis is set to report its Q2 earnings with analysts expecting an EPS of $2.17 and revenue of $14.07 billion, following a tough Q1 affected by major patent expirations. Despite revenue challenges, the company maintained strong cash flow of $3.30 b...
KeyCorp is set to report earnings with analysts forecasting a 20% increase in earnings per share to $0.42 and an 8% rise in total revenue to $1.97 billion. The growth is mainly driven by a 10% increase in net interest income, fueled by strong commerc...
Several biotech and manufacturing companies saw significant stock declines due to key corporate events. Vision Marine Technologies dropped nearly 24% after shifting its focus from boat manufacturing to a mining project, causing investor uncertainty. ...
